About IDM Pharma
IDM Pharma is a Healthcare company based in Irvine (United States) founded in 1990, and was acquired by Takeda in May 2009. Cancer immunotherapies were developed by this US-based biotech firm. The company was acqui-hired. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its competitors include C4 Therapeutics, Erasca and Revolution Medicines; 3 of its 3 listed competitors have raised funding.
Company details
IDM Pharma was founded in 1990 and headquartered in Irvine, United States, within the biotechnology sector. Focus was placed on developing immunotherapies for cancer treatment. MEPACT (mifamurtide) was advanced for osteosarcoma and received approval in Europe prior to the 2007 acquisition by Takeda. Development of Bexidem for bladder cancer was subsequently halted. Operations centered on innovative therapeutic solutions in oncology.
- Headquarters Irvine, United States
- Stage Acquired
- SectorsHealthcare
- Phone•••• ••••
- Website idm-pharma.com
- Social LinkedIn
- Acquired by Takeda (May 2009)
- Latest Funding Round$12.5M (USD), Post-IPO
Feb 2007
- InvestorsTakeda Pharmaceuticals
& 2 more
- Acquired byTakeda
(May 2009)
Funding Insights of IDM Pharma
- Total Rounds 1
- Last Round Post-IPO — $12.5M
- First Round $12.5M
(Feb 2007)
- Investors Count 2
All 1 funding rounds of IDM Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2007 | $12.5M | Post-IPO | – | – |
3 investors in total: 3 institutional.
Investors in IDM Pharma
IDM Pharma has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Takeda Pharmaceuticals, Palo Alto Investors and Alta Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare sector investments are managed through private equity strategies. | pa-investors.com | Palo Alto, United States | ||
Venture capital firm focused on healthcare companies | altapartners.com | Jackson, United States | ||
Takeda Pharmaceuticals is engaged in developing innovative medicines globally. | 1781 | takeda.com | Tokyo, Japan |
Investor details for IDM Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of IDM Pharma
3 dated milestones of IDM Pharma across 19 years, from founding to its latest funding, stage changes and deals.
- Founded IDM Pharma is founded.
- Funding First funding round of $12.5M.
- Exit Acquired by Takeda.
Competitors of IDM Pharma
IDM Pharma has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and Revolution Medicines.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. |
Detailed competitors of IDM Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as IDM Pharma (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about IDM Pharma
IDM Pharma was founded in 1990 and raised its 1st funding round 17 years after it was founded.
IDM Pharma is headquartered in Irvine, United States. It is registered at Irvine, California, United States.
IDM Pharma was founded in 1990 and headquartered in Irvine, United States, within the biotechnology sector. Focus was placed on developing immunotherapies for cancer treatment. MEPACT (mifamurtide) was advanced for osteosarcoma and received approval in Europe prior to the 2007 acquisition by Takeda. Development of Bexidem for bladder cancer was subsequently halted. Operations centered on innovative therapeutic solutions in oncology.
IDM Pharma's top competitors include C4 Therapeutics, Erasca and Revolution Medicines.
IDM Pharma has 3 investors. Key investors include Takeda Pharmaceuticals, Palo Alto Investors, and Alta Partners.
Yes. IDM Pharma was acquired by Takeda in May 2009.